ANNOUNCEMENT: Aetion expands its executive team with three new leaders

The addition of these leaders brings years of industry experience to the company, as Aetion continues to invest in future growth.

ANNOUNCEMENT: Aetion expands its executive team with three new leaders

The addition of these leaders brings years of industry experience to the company, as Aetion continues to invest in future growth.

NEW YORK, Nov. 8, 2022 /PRNewswire/ -- Aetion, the global leader in Real World Testing (RWE) technology and analytics, today announced the appointments of Professor Dorothee Bartels as Chief Digital Officer, Jade Cusick as Chief Commercial Officer and Jeremy Brody as chief strategy officer. Together, they will accelerate Aetion's drive to serve life sciences customers, regulators and payers in the US and Europe.

"At this critical time of growing demand for real-world evidence, Dorothee, Jade and Jeremy bring unparalleled healthcare experience and business acumen to Aetion's leadership team," said Carolyn Magill, CEO and Chairman of the Board of Aetion. Aetion. "His track record demonstrates a passion for using data and analytics to unite stakeholders in improving patient health outcomes."

Trained as an epidemiologist, Bartels has led global teams in implementing innovative and thoughtful Real World Evidence (RWE) solutions that emphasize impact and scalability. He has held leadership roles in epidemiology and digital innovation at UCB and Boehringer-Ingelheim and was a real-world and clinical data strategy lead for X, the Moonshot Factory.

Recognized as one of PharmaVOICE's 2021 Most Inspiring Leaders in Life Sciences, Cusick has dedicated his career to finding customer-centric solutions to the toughest problems in healthcare. Most recently, Cusick was Global Director of Client Partnership and Marketing at Cerner Enviza, a division of Oracle, and prior to that he was instrumental in driving growth at Kantar Health.

Brody is known for the business transformations he has led at Kantar Health and Cerner and for seeing possibilities where others cannot. As the leader of corporate development and innovation, he forged partnerships that resulted in significant company growth and value for patients.

"We're starting to see accelerated progress in using real-world evidence to expand what we know about medicines and how they're used to benefit patients," said Dr. Scott Gottlieb, former U.S. Drug and Drug Administration Commissioner. Foods of America and member of the Board of Directors of Aetion. "Aetion's real-world evidence technology and expertise are well-suited to fulfilling the promise of real-world data to further inform the safe use of medicines that will lead to better health outcomes."

About Aetion

Aetion is a healthcare analytics company that provides real-world evidence for manufacturers, purchasers and regulators of medical technologies and treatments. Aetion Evidence Platform® analyzes real-world data to produce transparent, rapid, and scientifically validated answers about safety, efficacy, and value. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs the most critical decisions in healthcare—what works best, for whom, and when—to guide development of products, marketing and payment innovation. Learn more at aetion.com and follow us @aetioninc.

logo - link

View original content: enlace

Yorum yapabilmek için üye girişi yapmanız gerekmektedir.

Üye değilseniz hemen üye olun veya giriş yapın.

NEXT NEWS